О письме
McKinsey & Company отправил это письмо 21 февраля 2026, 17:08. Тема: «GLP-1s are just the beginning». В архиве Валеры письмо сохранено как скриншот рассылки с адреса publishing@email.mckinsey.com. Ниже — краткий текстовый фрагмент для ознакомления и полный вид письма на скриншоте.
Текст письма
McKinsey & Company Share this email New from McKinsey & Company GLP-1s are just the beginning
GLP-1 therapies are on track to become one of the fastest-growing drug classes in history. Sales are expected to reach $100 billion by 2030 . But the real opportunity is bigger than weight loss.
Obesity—once seen as an intractable condition—is now widely recognized as a treatable disease and part of a broader metabolic health crisis shaping healthcare costs, workforce productivity, and consumer demand worldwide.
Полный вид письма — на скриншоте.
Кнопки и ссылки в письме
- GLP-1
- Lars Hartenstein
- recent episode
- Read more
- Explore
